Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Short term Debt (2021 - 2025)

Historic Short term Debt for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Q3 2025 value amounting to $20.0 million.

  • Harmony Biosciences Holdings' Short term Debt rose 3333.33% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year increase of 3333.33%. This contributed to the annual value of $16.2 million for FY2024, which is 833.33% up from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Short term Debt stood at $20.0 million for Q3 2025, which was up 3333.33% from $18.8 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Short term Debt registered a high of $20.0 million during Q3 2025, and its lowest value of $2.0 million during Q3 2021.
  • Over the past 5 years, Harmony Biosciences Holdings' median Short term Debt value was $15.0 million (recorded in 2023), while the average stood at $10.4 million.
  • As far as peak fluctuations go, Harmony Biosciences Holdings' Short term Debt changed by 0.0% in 2022, and later skyrocketed by 65000.0% in 2023.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Short term Debt stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then skyrocketed by 650.0% to $15.0 million in 2023, then increased by 8.33% to $16.2 million in 2024, then increased by 23.08% to $20.0 million in 2025.
  • Its last three reported values are $20.0 million in Q3 2025, $18.8 million for Q2 2025, and $17.5 million during Q1 2025.